反应详情

This was prepared using the same procedure as for (4-(6-bromo-7-(4-(pyridin-3-ylmethyl)piperazin-1-yl)-3H-imidazo[4,5-b]pyridin-2-yl)phenyl)methanamine, but here using tert-butyl 2-(6-bromo-7-(4-(pyridin-3-ylmethyl)piperazin-1-yl)-3H-imidazo[4,5-b]pyridin-2-yl)ethylcarbamate (20 mg, 0.058 mmol), TFA (0.2 mL) and CH2Cl2 (1 mL). The same purification procedure gave the desired product (15 mg, 93%) as a colourless solid; δH (500 MHz, DMSO-d6) 2.58 (s, br, 4H, piperazine N(CH2)2), 2.87 (t, J=6.7 Hz, 2H, CH2CH2NH2), 3.00 (t, J=6.8 Hz, 2H, CH2CH2NH2), 3.55 (t, J=4.5 Hz, 4H, piperazine N(CH2)2), 3.61 (s, 2H, NCH2Ar), 7.39 (dd, J=7.8, 4.8 Hz, 1H, pyridine H-5), 7.77 (d, br, J=7.8 Hz, 1H, pyridine H-4), 8.18 (s, 1H, imidazo[4,5-b]pyridine H-5), 4.49 (dd, J=4.7, 1.0 Hz, 1H, pyridine H-6), 8.55 (d, J=1.1 Hz, 1H, pyridine H-2);

1. customThis was prepared
2. customThe same purification procedure